Showing results (1841-1850 of 1,933) with videos related to
Sort By:
Pageof 194
Hepatology International|February 26, 2021
Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patientsMaaike Biewenga, Monique K van der Kooij, Michel W J M Wouters, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2013
Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropeniaMaureen J Aarts, Janneke P Grutters, Frank P Peters, et al.British Journal of Cancer|October 10, 2018
Risk of diabetes after para-aortic radiation for testicular cancerHarmke J Groot, Jourik A Gietema, Berthe M P Aleman, et al.Scientific Reports|May 16, 2024
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanomaLindsay V M Leek, Jessica C L Notohardjo, Karlijn de Joode, et al.Cancers|May 13, 2020
Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic TherapyStephanie A Blankenstein, Maureen J B Aarts, Franchette W P J van den Berkmortel, et al.Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 22, 2025
Development of a Decision Model to Estimate the Outcomes of Treatment Sequences in Advanced MelanomaSaskia de Groot, Hedwig M Blommestein, Brenda Leeneman, et al.Cancer|January 10, 2024
BRAF/MEK inhibitor rechallenge in advanced melanoma patientsOlivier J Van Not, Alfons J M van den Eertwegh, John B Haanen, et al.European Journal of Cancer (Oxford, England : 1990)|February 11, 2023
Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment RegistryJesper van Breeschoten, Alfons J M van den Eertwegh, Doranne L Hilarius, et al.European Journal of Cancer (Oxford, England : 1990)|February 6, 2025
Cost-effectiveness of treatment sequences for BRAF-mutant advanced melanoma in the Netherlands using a health economic modelHedwig M Blommestein, Saskia de Groot, Brenda Leeneman, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2020
Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based StudyMichiel C T van Zeijl, John B A G Haanen, Michel W J M Wouters, et al.Pageof 194